1626 Results (Page 1 of 136)
Rare Diseases Markets Research Reports
Brazil Multiple Myeloma Therapeutics Market Analysis
Brazil's multiple myeloma therapeutics market has valued at $209 Mn in 2022 and is estimated to expand at a CAGR of 5.5% from 2022 to 2030 and will reach $320 Mn in 2030. Brazil One of the main reasons propelling the growth of this market is advancements in diagnostic and treatment technologies, and the aging population. The Market is segmented by type, drug, and distribution channel. Some key players in this market are Ache Laboratories Pharmaceutics, Eurofarma Laboratories, Biolab Sanus Pharmaceutical, Libbs Pharmaceutical, Cristalia Products Químicos Pharmaceuticals, Blau Pharmaceutical, Sanofi, EMS, Hypermarcas and others.
UAE Multiple Myeloma Therapeutics Market Analysis
UAE's multiple myeloma therapeutics market was valued at $42 Mn in 2022 and is estimated to expand at a CAGR of 5.5% from 2022 to 2030 and will reach $64 Mn in 2030. One of the main reasons propelling the growth of this Market is the growing demand for innovative therapies and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Julphar, Neopharma, Medpharma, LifePharma, Gulf Pharmaceutical, Pharmax Pharmaceuticals, and others.
India Multiple Myeloma Therapeutics Market Analysis
India's multiple myeloma therapeutics market was valued at $152 Mn in 2022 and is estimated to expand at a CAGR of 7.5% from 2022 to 2030 and will reach $271 Mn in 2030. One of the main reasons propelling the growth of this market is the increase in prevalence, Increasing awareness, and screening programs. The Market is segmented by type, drug, and distribution channel. Some key players in this market are Natco Pharma, Cipla, Hetero Drugs, Biocon, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Lupin, Cadila Healthcare, and others.
Australia Multiple Myeloma Therapeutics Market Analysis
Australia's multiple myeloma therapeutics market was valued at $100 Mn in 2022 and is estimated to expand at a CAGR of 6% from 2022 to 2030 and will reach $160 Mn in 2030. One of the main reasons propelling the growth of this Market is Increasing healthcare expenditure, Increasing geriatric population. The Market is segmented by type, drug, and distribution channel. Some key players in this Market are CSL, Telix Pharmaceuticals, Mesoblast, Kazia Therapeutics, Immutep, Patrys, Actinogen Medical, Noxopharm, Prima BioMed, Polynovo, and others.
Egypt Multiple Myeloma Therapeutics Market Analysis
Egypt's multiple myeloma therapeutics market was valued at $23 Bn in 2022 and is estimated to expand at a CAGR of 6% from 2022 to 2030 and will reach $37 Bn in 2030. One of the main reasons propelling the growth of this market is growing awareness and diagnosis, technological advancements. The market is segmented by type, drug, and distribution channel. Some key players in this market are EIPICO, Amoun Pharmaceutical Company, Pharco Pharmaceuticals, Delta Pharma, MEMI Pharmaceuticals, and others.
US Multiple Myeloma Therapeutics Market Analysis
The US Multiple Myeloma Therapeutics Market was valued at $3.5 Bn in 2022 and is estimated to expand at a CAGR of 2.5% from 2022 to 2030 and will reach $4.26 Bn in 2030. One of the main reasons propelling the growth of this Market is advancements in therapeutic development and increased funding for research and development. The market is segmented by type, drug, and distribution channel. Some key players in this Market are Takeda Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, Amgen, AbbVie, Novartis, GlaxoSmithKline, Sanofi and others.
UK Multiple Myeloma Therapeutics Market Analysis
The UK Multiple Myeloma Therapeutics Market was valued at $217 Mn in 2022 and is estimated to expand at a CAGR of 2.5% from 2022 to 2030 and will reach $264 Mn in 2030. One of the main reasons propelling the growth of this Market is increase in chronic disease, aging population. The Market is segmented by type, drug and distribution channel. Some key players in this Market are Takeda, Amgen, Janssen-Cilag, Celgene, AstraZeneca and others.
Italy Multiple Myeloma Therapeutics Market Analysis
The Italy Multiple Myeloma Therapeutics Market was valued at $200 Mn in 2022 and is estimated to expand at a CAGR of 4% from 2022 to 2030 and will reach $274 Mn in 2030. One of the main reasons propelling the growth of this Market is Advancements in technology, aging population. The Market is segmented by type, drug and distribution channel. Some key players in this Market are Menarini Group, Sigma-Tau Group, Chiesi Pharmaceutics and others.
Spain Multiple Myeloma Therapeutics Market Analysis
The Spain Multiple Myeloma Therapeutics Market was valued at $161 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 3.5% from 2022 to 2030 and will reach $212 Mn in 2030. One of the main reasons propelling the growth of this Market is increase in Introduction of innovative therapies, aging population. The Market is segmented by type, drug and distribution channel. Some key players in this Market are Janssen-Cilag S.A, Celgene, Amgen, Takeda, Laboratories Rovi, and others.
China Multiple Myeloma Therapeutics Market Analysis
The China Multiple Myeloma Therapeutics Market was valued at $670 Mn in 2022 and is estimated to expand at a CAGR of 7.5% from 2022 to 2030 and will reach $1069 Mn in 2030. One of the main reasons propelling the growth of this Market is Rising disposable income, aging population. The Market is segmented by type, drug and distribution channel. Some key players in this Market are BeiGene, Innovent Biologics, Simcere, Hengrui Medicine, CSPC Pharmaceutical and others.
France Multiple Myeloma Therapeutics Market Analysis
The France Multiple Myeloma Therapeutics Market was valued at $229 Mn in 2022 and is estimated to expand at a CAGR of 3.5% from 2022 to 2030 and will reach $302 Mn in 2030. In One of the main reasons propelling the growth of this Market is Government initiatives and funding, aging population. The Market is segmented by type, drug and distribution channel. Some key players in this Market are Onxeo, Nanobiotix, AB Science, Servier, Sigma Aldrich and others.
Canada Multiple Myeloma Therapeutics Market Analysis
Canada's Multiple Myeloma Therapeutics Market was valued at $667 Mn in 2022 and is estimated to expand at a CAGR of 4.5% from 2022 to 2030 and will reach $849 Mn in 2030. One of the main reasons propelling the growth of this Market is the increasing adoption of combination therapies and technological advancements. The Market is segmented by type, drug and distribution channel. Some key players in this market are Apobiologix, Knight Therapeutics., Medexus Pharmaceuticals, Therapure Biopharma, Bloom Burton & Co., and others.
Germany Multiple Myeloma Therapeutics Market Analysis
Germany's Multiple Myeloma Therapeutics Market was valued at $305 Mn in 2022 and is estimated to expand at a CAGR of 2.7% from 2022-30 and will reach $378 Mn in 2030. One of the main reasons propelling the growth of this Market is an increase in chronic disease, Increasing adoption of combination therapies. The Market is segmented by type, drug and distribution channel. Some key players in this Market are Abbott, MorphoSys, Merck, Medigene, Affimed, Helios Hospital, Vivantes Hospital Group and others.
Canada Primary Hyperoxaluria (PH) Drugs Market Analysis
Canada Primary Hyperoxaluria (PH) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Unmet Medical Need, Increasing Awareness and Diagnosis, Advancements in Research and Development, Growing Investment and Pipeline Development, Collaboration and Patient Advocacy,rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Drugs Market are Allena Pharmaceuticals, Inc., Intellia Drugs, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.
France Cystic Fibrosis (CF) Therapeutics Market Analysis
France Cystic Fibrosis (CF) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Cystic fibrosis (abbreviated CF) is a genetic disorder that causes mucus to build up in certain organs of the body, particularly the lungs and pancreas, resulting in breathing problems, respiratory infections and faulty digestion. The increasing prevalence of Cystic Fibrosis (CF) coupled with the rising treatment rate is one of the key factors anticipated to propel the demand for cystic fibrosis therapeutics over the forecast period. The key players are consistently involved in the development of new or combination of products to treat cystic fibrosis. Investment in the R&D is one of the strategic measures to beat the competition. The key players in this market are AbbVie Inc.; F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd; Merck & Co. Inc.; Alcresta Therapeutics Inc.; Allergan; and AstraZeneca.
Spain Morquio Syndrome (MPS-IV) Therapeutics Market Analysis
Spain Morquio Syndrome (MPS-IV) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. As genetic illnesses like Morquio Syndrome (MPS-IV) has become more common, there is an increasing demand for specialised drugs to treat them. Major global players in Morquio Syndrome (MPS-IV) Therapeutics Market are BioMarin, Genzyme Corporation, Shire, JCR Pharmaceuticals Co., Ltd., Sanofi, Sangamo Therapeutics, ArmaGen and GREEN CROSS CORP, Concert Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., and other players.
India AADC Deficiency Market Analysis
India AADC Deficiency Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The growing awareness of rare diseases like AADC deficiency among the general public and medical community is one of the major factors influencing market expansion. More cases are being diagnosed as the illness gains recognition, which results in early treatment and better patient outcomes. As medical professionals become more familiarized with the illness and its symptoms, it is expected that this tendency will continue.Major global players in AADC Deficiency Market are Lysogene, Retrophin, Ultragenyx Pharmaceutical, PTC Therapeutics, Azevan Pharmaceuticals, Neurocrine Biosciences, Adrenomed AG, Renova Therapeutics, Titan Pharmaceuticals, Voyager Therapeutics.
Australia Leukocyte Adhesion Deficiency (LAD-I) Market Analysis
Australia Leukocyte Adhesion Deficiency (LAD-I) therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. An uncommon genetic condition called leukocyte adhesion deficiency (LAD-I) impairs the immune system's capacity to combat infections. There is currently no cure for LAD-I, and there are few effective treatments available. To fill this unmet medical need, new medicines are becoming more and more popular. Vertex Pharmaceuticals, Orpha Labs, Avalo Therapeutics, Inc., Rocket Pharmaceuticals, Inc., Aspen Neuroscience, Magenta Therapeutics, Rubius Therapeutics, Enochian Biosciences, Sana Biotechnology, and Sigma-Aldrich are major global players.
Egypt Uveitis Therapeutics Market Analysis
Egypt Uveitis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Uveitis is an inflammation of the uvea, which is the middle layer of the tissue that surrounds the eye and is made up of the iris, ciliary body, and choroid. The most typical extra-articular Spondyloarthritis symptom is uveitis (SpA) Increased healthcare financing, together with the development of drugs with improved efficacy and fewer side effects, has benefited technological advancements in the field, which together are serving as a potential driver of the uveitis therapeutic market. Several well-known companies involved in the development and marketing of uveitis medicines include Novartis AG, Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Johnson & Johnson, AbbVie Inc., and Allergan (now a division of AbbVie).
Canada Pyruvate Kinase (PK) Deficiency Market Analysis
Canada Pyruvate Kinase (PK) deficiency market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pyruvate Kinase (PK) deficiency is growing rapidly as a result of increase in incidence and prevalence of disease, increased awareness about the disease, improved diagnostic techniques, advancements in treatment options, increase in research and development and rise in patient assistance programmes. Agios pharmaceuticals, Pfizer Inc., Sanofi, Novartis, Teva Pharmaceutical Industries Ltd, Green cross corporation are the top key market players operating in the global Pyruvate Kinase (PK) deficiency market.
France Cytomegalovirus Therapeutics Market Analysis
France Cytomegalovirus Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A member of the Herpesviridae family with an envelope, the human herpesvirus 5 (HHV-5) is also referred to as cytomegalovirus. Around 40% to 100% of adults worldwide have experienced HHV-5 exposure at some point in their lifetime, making it a very common virus. A rise in the frequency of cytomegalovirus infection, investments in research & development, and the introduction of novel medicines are some of the reasons driving the growth of the market for cytomegalovirus therapeutics. Several Global pharmaceutical firms, including Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, MEMO Therapeutics, Lion TCR, and others are active in this Cytomegalovirus Therapeutics market.
Spain Mucopolysaccharidosis I (MPS-I) Therapeutics Market Analysis
Spain Mucopolysaccharidosis I (MPS-I) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in this market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
India Acute Myeloid Leukemia Market Analysis
India Acute Myeloid Leukemia Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The ageing population, higher drug approval rates, the designation of acute myeloid leukaemia as an orphan disease, and rising healthcare costs are anticipated to drive the market. One of the factors accelerating the market's growth is the technological advancement made possible by the capacity to recognise damaged cells. Major global players in Acute Myeloid Leukemia Market are Ambit Biosciences Corporation, Genzyme Corporation, Celgene Corporation, Clavis Pharma ASA, Sunesis Pharmaceuticals, Cephalon, Bristol-Myers Squibb, Novartis International AG, GlaxoSmithKline.
Australia Lysosomal Storage Disorders Drugs Market Analysis
Australia Lysosomal Storage Disease Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The rise in lysosomal diseases, greater public awareness of unusual lysosomal storage disorders, increased research and development for diagnostics, and increased drug development for treating lysosomal diseases are the main drivers impacting the market for lysosomal storage disease treatments. Major global players in Lysosomal Storage Disease Drugs Market are Pfizer Inc, Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi (Genzyme Corporation), BioMarin, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Amicus Drugs, Inc, Alexion Pharmaceuticals, Inc, Sigilon Drugs, Inc, and Orphazyme A/S are some of the companies that participate in this industry.
Egypt Anthrax Therapeutics Market Analysis
Egypt Anthrax therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Bacillus anthracis is the bacteria that causes anthrax (B. anthracis). The market for anthrax therapeutics is fueled by factors such the increased prevalence of bacterial infections, rising research funding, the development of innovative medicines for treating anthrax, and pipeline goods, which increase demand and stimulate market expansion. The current rise in healthcare spending in both developed and developing nations is anticipated to give manufacturers a competitive edge in the development of novel and ground-breaking products. Global industries in the Anthrax therapeutics market are Aristo Pharmaceuticals Private Limited, Indoco Remedies Ltd., Lupin, Deinove, Bayer AG, Pfizer Inc., Emergent, Soligenix, Zydus Group, Sanofi, Alembic Pharmaceuticals, Emergent, Sanofi, Porton Biopharma, Lupin, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd and many more